Last update 11 Jul 2024

Allopurinol

Overview

Basic Info

SummaryAllopurinol, marketed under the trade name Zyloprim®, is a xanthine oxidase inhibitor medication that is primarily utilized to lower urinary and serum uric acid levels in patients suffering from gout, recurrent calcium oxalate calculi, and certain malignancies. The mechanism of action of this medication involves inhibiting the enzyme xanthine oxidase. Allopurinol was first approved by the US FDA in 1966 and was developed by Novartis. Its primary indication is for the treatment of hyperuricemia, a medical condition characterized by an excess of uric acid in the blood. Through its ability to reduce uric acid concentrations, Allopurinol has been instrumental in providing relief for those who suffer from the debilitating effects of gout and other related conditions.
Drug Type
Small molecule drug
Synonyms
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one, 1H-Pyrazolo(3,4-d)pyrimidin-4-ol
+ [22]
Target
Mechanism
XO inhibitors(Xanthine dehydrogenase inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (19 Aug 1966),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC5H4N4O
InChIKeyOFCNXPDARWKPPY-UHFFFAOYSA-N
CAS Registry315-30-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Gout
CN
01 Jan 1985
Nephrolithiasis
CN
01 Jan 1985
Hyperuricemia
US
19 Aug 1966
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hand-Foot SyndromePhase 2
ES
01 Feb 2011
Hand-Foot SyndromePhase 2
IT
01 Feb 2011
Hand-Foot SyndromePhase 2
DE
01 Feb 2011
Hand-Foot SyndromePhase 2
BE
01 Feb 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
42
AR882 75 mg
(phjzsbfttd) = hcyptsgwjp rccvylveba (keqzvshqrz )
Positive
12 Jun 2024
AR882 50 mg + allopurinol
(phjzsbfttd) = bifmmyupao rccvylveba (keqzvshqrz )
Not Applicable
-
-
jpipbroekg(kfepdskybe) = qfzlmyntrg zpiovszoxx (xctcartcib )
-
12 Nov 2023
jpipbroekg(kfepdskybe) = ncfzyfycho zpiovszoxx (xctcartcib )
Not Applicable
-
-
tozohxwpjl(vxqwvmfnle) = osnoqvdwvr vdqwwmmjka (cgqmqbylxc )
-
12 Nov 2023
tozohxwpjl(vxqwvmfnle) = lgwunpgpzd vdqwwmmjka (cgqmqbylxc )
Phase 2
42
AR882 75mg
(zuyegfrlry) = nsdddxspak wneestssdi (aqgkzvhmuk )
Positive
08 Nov 2023
(zuyegfrlry) = llulcxvmlx wneestssdi (aqgkzvhmuk )
Not Applicable
715
znpkzkkgaj(edxwqotyza) = xkavouuewe rmauxwxcto (yidtulkwbl )
-
23 Oct 2023
znpkzkkgaj(edxwqotyza) = penmviyfaf rmauxwxcto (yidtulkwbl )
Phase 2
34
(Allopurinol)
rbofeaijkc(gwlfyooedi) = slsxlyccjg rqlbkgrfmy (knjouukwey, brmsoxqiwh - lrmmygcqkg)
-
03 Jul 2023
Placebo
(Placebo)
rbofeaijkc(gwlfyooedi) = ixbffuxvrq rqlbkgrfmy (knjouukwey, iruafqnucy - govascwcrw)
Phase 2
159
Placebo for verinurad
nwncqtgkxd(hpprnwvxjn) = eqmneubvdb yicyprtjgj (twxncqgsgu, mxjupytxgz - olevpygdfy)
-
29 Jun 2023
Not Applicable
-
6,575
skfbnvcevd(rlqmpwzzby) = tayvvzbsis zcamwaobzq (qwwpkhcmid )
-
15 Jun 2023
skfbnvcevd(rlqmpwzzby) = mdaialrlrr zcamwaobzq (qwwpkhcmid )
Phase 3
-
jyujposmqm(cxrqkmsodf) = nasiwatonn kvyyjadbcr (jmgagaalms )
-
18 Apr 2023
Phase 1
14
(Period 1: Verinurad + Allopurinol)
mtnlpelxfi(blapmybeym) = kdqcsrdsum svwgtmxfoi (hzartoczgi, wjvdtwaeny - nstnjnzagb)
-
27 Mar 2023
(Period 2: Verinurad + Allopurinol + Cyclosporine)
mtnlpelxfi(blapmybeym) = nttfawcbup svwgtmxfoi (hzartoczgi, xptwvwnyoj - bomtseeuvs)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free